Empagliflozin vs Enavogliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01131676 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).

Next expected readout: November 2026 · NCT05057806 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)

Result source: NCT01131676

Enavogliflozin · Envlo

Marketed by Daewoong Pharmaceutical and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04634500 · Phase 3 · completed

This Phase 3 trial randomly assigned 200 people with type 2 diabetes to enavogliflozin or to dapagliflozin, with participants and investigators unaware of assignment. It was designed to show enavogliflozin was not worse than dapagliflozin at lowering HbA1c over 24 weeks, within a margin of 0.35 percentage points. It met that test: HbA1c fell by 0.80 percentage points on enavogliflozin against 0.75 on dapagliflozin, a difference of 0.04 points (95% CI -0.21 to 0.12).

Next expected readout: December 2026 · NCT06399835 (registry estimate)

Reported efficacy

Change from baseline in HbA1c (at 24 weeks): Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% (met)

Result source: NCT04634500

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmpagliflozinEnavogliflozin
HbA1c, change-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
-0.8% vs -0.8%avs dapagliflozinwk 24NCT04634500
Body weight, change (kg)-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003
—Not posted · NCT05376969
HbA1c below 7%34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
—Not posted · NCT05376969
Fasting plasma glucose, change-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
—Not posted · NCT05376969
3-point MACE (% with event)10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676
—Not posted · NCT05376969

HbA1c, change

Empagliflozin
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
Enavogliflozin
-0.8% vs -0.8%avs dapagliflozinwk 24NCT04634500

Body weight, change (kg)

Empagliflozin
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003
Enavogliflozin
—Not posted · NCT05376969

HbA1c below 7%

Empagliflozin
34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
Enavogliflozin
—Not posted · NCT05376969

Fasting plasma glucose, change

Empagliflozin
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
Enavogliflozin
—Not posted · NCT05376969

3-point MACE (% with event)

Empagliflozin
10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676
Enavogliflozin
—Not posted · NCT05376969
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Empagliflozin: 4 of 4 rows · Enavogliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmpagliflozinEnavogliflozin
Dropout rate
23.7%10 mga
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
23.2%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
8%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
8.7%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
15.9%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
6.2%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
11.2%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
4.4%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
9.4%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
6.1%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
2.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.5%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
18.1%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
10.2%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
7.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5.3%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
7.7%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
8.6%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6.4%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
7.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
—
Discontinued due to AEs
11.4%10 mga
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
11.6%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.9%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
3.2%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.6%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
5.6%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.3%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.1%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
1.7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
2.4%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
0%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.9%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.3%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
—10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
5.9%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
1.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
—
Serious AEs
37.4%10 mga
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
39%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
4.9%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.2%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
0.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
5.4%10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
0%25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
12.3%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
10.5%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
8.9%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
6.3%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
13.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
9.6%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.7%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0.6%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
1.8%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
3.8%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
2.3%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
0.9%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
3.2%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
—
Most frequent reported AEs
10 mga
hypoglycaemia 29.6% (placebo 29.4%)
urinary tract infection 14.5% (placebo 14.7%)
hyperglycaemia 9.3% (placebo 18.1%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 37 more results
25 mg
hypoglycaemia 28.7% (placebo 29.4%)
urinary tract infection 14.4% (placebo 14.7%)
nasopharyngitis 9.4% (placebo 9.3%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10mg
hypoglycaemia 15.6% (placebo 9.8%)
urinary tract infection 9.4% (placebo 6.7%)
nasopharyngitis 8% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 5.5% (placebo 4.9%)
urinary tract infection 4.1% (placebo 6.7%)
hyperglycaemia 2.3% (placebo 12.4%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 12.9% (placebo 9.8%)
urinary tract infection 6.9% (placebo 6.7%)
nasopharyngitis 6% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 8.9% (placebo 9.8%)
hyperglycaemia 7.9% (placebo 12.4%)
nasopharyngitis 5% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7% (placebo 4.9%)
upper respiratory tract infections 4.2% (placebo 5.3%)
urinary tract infection 4.2% (placebo 6.7%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7.2% (placebo 4.9%)
urinary tract infection 7.2% (placebo 6.7%)
diarrhoea 5.8% (placebo 0%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
10 mg
headache 16.2% (placebo 15.5%)
hypoglycaemia 16.2% (placebo 12.1%)
vitamin d deficiency 13.5% (placebo 13.8%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
25 mg
hypoglycaemia 17.2% (placebo 12.1%)
blood ketone body increased 10.3% (placebo 3.4%)
headache 10.3% (placebo 15.5%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
10 mg
constipation 10.8% (placebo 4.7%)
pyrexia 6.2% (placebo 4.7%)
nasopharyngitis 4.6% (placebo 6.3%)
NCT04531462 · Phase 4 · registry result, not featured evidence
10 mg
nasopharyngitis 34.9% (placebo 31.1%)
hypoglycaemia 27.9% (placebo 21.1%)
pollakiuria 10.5% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
25 mg
hypoglycaemia 27.8% (placebo 21.1%)
nasopharyngitis 26.7% (placebo 31.1%)
pollakiuria 10% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
10 mg
viral upper respiratory tract infection 31.3%
fall 3.1%
influenza 0%
NCT02589626 · Phase 4 · registry result, not featured evidence
25mg
viral upper respiratory tract infection 33.3%
influenza 9.1%
fall 6.1%
NCT02589626 · Phase 4 · registry result, not featured evidence
10 mg
hypoglycaemia 20.5% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg
hypoglycaemia 15.1% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg-25 mg
lipase increased 7.5% (placebo 3.9%)
cough 6.3% (placebo 1.3%)
upper respiratory tract infection 2.5% (placebo 5.2%)
NCT02182830 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg qd
dyslipidaemia 8.7%
urinary tract infection 7%
upper respiratory tract infection 2.9%
NCT01719003 · Phase 3 · registry result, not featured evidence
25 mg qd
urinary tract infection 7.8%
dyslipidaemia 6.6%
upper respiratory tract infection 4.2%
NCT01719003 · Phase 3 · registry result, not featured evidence
12.5 mg Bid + 1000 mg Bid
diarrhoea 7.5%
dizziness 5.7%
gastritis 5.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 1000 mg Bid
urinary tract infection 10.6%
diarrhoea 7.1%
dyslipidaemia 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 500 mg Bid
urinary tract infection 10%
dizziness 5.3%
diarrhoea 3.5%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 1000 mg Bid
urinary tract infection 7%
dyslipidaemia 4.7%
upper respiratory tract infection 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 500 mg Bid
dyslipidaemia 8.9%
diarrhoea 5.3%
urinary tract infection 5.3%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10 mg
nasopharyngitis 10% (placebo 4.8%)
anal inflammation 0% (placebo 0%)
bartholinitis 0% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
25 mg
anal inflammation 5.3% (placebo 0%)
bartholinitis 5.3% (placebo 0%)
pollakiuria 5.3% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
25 mg
ketosis 19.4% (placebo 3.3%)
fatigue 9.7% (placebo 0%)
headache 9.7% (placebo 10%)
NCT02632747 · Phase 2 · registry result, not featured evidence
10 mg QD
urinary tract infection 6.8% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
25 mg QD
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
12.5 mg BID
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
5 mg BID
urinary tract infection 3.7% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
—

Notes

  1. aPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Empagliflozin

MACE 3-point Composite 10.4% (n=2345) vs 12.1% (n=2333) placebo10 mg
event count · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
10.5% (n=2342) vs 12.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10.5% (n=4687) vs 12.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
MACE 4-point Composite 12.8% (n=2345) vs 14.3% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
12.8% (n=2342) vs 14.3% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
12.8% (n=4687) vs 14.3% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Silent MI 1.6% (n=1174) vs 1.2% (n=1211) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
1.6% (n=1204) vs 1.2% (n=1211) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
1.6% (n=2378) vs 1.2% (n=1211) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
HF Hospitalization 2.6% (n=2345) vs 4.1% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
2.8% (n=2342) vs 4.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7% (n=4687) vs 4.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Albuminuria 51.5% (n=1403) vs 51.2% (n=1374) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
51.5% (n=1376) vs 51.2% (n=1374) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
51.5% (n=2779) vs 51.2% (n=1374) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Macroalbuminuria 10.9% (n=2037) vs 16.2% (n=2033) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
11.5% (n=2054) vs 16.2% (n=2033) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
11.2% (n=4091) vs 16.2% (n=2033) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Composite Microvascular Outcome 13.9% (n=2057) vs 20.5% (n=2068) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
14.1% (n=2075) vs 20.5% (n=2068) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
14% (n=4132) vs 20.5% (n=2068) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Weight -2.08 vs -0.45 placebo kg @ 24wk10mg
absolute change · kg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
show 18 more results
-2.16 vs -0.45 placebo kg @ 24wk10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.79 vs -0.04 placebo kg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
1.29 vs -0.04 placebo kg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-1.99 vs 0.01 placebo kg @ 24wk10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
-2.21 vs -0.98 placebo kg @ 24wk10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
-2.39 vs -1.27 Metformin kg @ 24wk10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
-2.46 vs -0.45 placebo kg @ 24wk25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
-1.33 vs -0.45 placebo kg @ 24wk25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
-2.39 vs -0.45 placebo kg @ 24wk25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.29 vs -0.45 placebo kg @ 24wk25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.31 vs 0.01 placebo kg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
-2.38 vs -1.27 Metformin kg @ 24wk25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
-2.52 vs -0.3 placebo kg @ 24wk25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-3.78 vs -1.27 Metformin kg @ 24wk12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
-3.04 vs -1.27 Metformin kg @ 24wk12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
-3.06 vs -0.3 placebo kg @ 24wk10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
-3.48 vs -1.27 Metformin kg @ 24wk5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
-2.77 vs -1.27 Metformin kg @ 24wk5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
Daily Plasma Glucose Change mg/dL -0.54 vs -0.11 placebo mmol/L @ 24wk10mg
absolute change · mmol/L
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -9.64 mg/dL as posted
show 5 more results
-0.56 vs -0.11 placebo mmol/L @ 24wk*10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.01 mg/dL as posted
-0.8 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.36 mg/dL as posted
-1.97 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -35.47 mg/dL as posted
-0.72 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -13.06 mg/dL as posted
-1.63 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -29.34 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk10 mg, 25 mg
responder rate · % of participants
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Time to Treatment Failure 5.5 vs 2.16 placebo months10 mg, 25 mg
time to event · months
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 · converted to months from 167.333 days as posted
Fasting Plasma Glucose Change mg/dL -19.48 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
absolute change · mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 3 more results
-18.45 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-25.61 vs -5.56 placebo mg @ 24wk10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
-29.69 vs -5.56 placebo mg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence

+ 24 further endpoints in the CSV export.

Chronic Kidney Disease

Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT03594110 · Phase 3 · completed

Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).

Next expected readout: December 2026 · NCT05786443 (registry estimate)

Reported efficacy

Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)

Result source: NCT03594110

Enavogliflozin · Envlo

Marketed by Daewoong Pharmaceutical and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmpagliflozinEnavogliflozin
Kidney composite outcome6.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110
—Trial running · NCT06606093
UACR, % change-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840
—Trial running · NCT06606093
eGFR slope—Not posted · NCT05373680—Trial running · NCT06606093
Haemoglobin, change—Not posted · NCT05373680—Trial running · NCT06606093

Kidney composite outcome

Empagliflozin
6.1% vs 8.1%−2 vs placebo10 mg · n 3304NCT03594110
1 other result
  • 7.5% vs 8.9% 10 mg · n 3304 · Phase 3 · secondary NCT03594110
Enavogliflozin
—Trial running · NCT06606093

UACR, % change

Empagliflozin
-39.1% vs -2.6%−36.5 vs placebo10 mg · wk 14 · n 61NCT05182840
5 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840
Enavogliflozin
—Trial running · NCT06606093

eGFR slope

Empagliflozin
—Not posted · NCT05373680
Enavogliflozin
—Trial running · NCT06606093

Haemoglobin, change

Empagliflozin
—Not posted · NCT05373680
Enavogliflozin
—Trial running · NCT06606093
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Enavogliflozin: no structured comparison results are available for Chronic Kidney Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Empagliflozin: 4 of 4 rows · Enavogliflozin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmpagliflozin
Dropout rate
22.9%10 mga
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
7.2%10 mga
NCT03594110 · Phase 3
show 9 more results
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
—10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
—3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Serious AEs
33%10 mga
NCT03594110 · Phase 3
show 9 more results
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
5.6%10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
8.3%20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
9.6%10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
6.8%10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
5.3%10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
4.3%3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mga
gout 6.9% (placebo 7.9%)
NCT03594110 · Phase 3
show 8 more results
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
10 mg
glomerular filtration rate decreased 9.9% (placebo 4.1%)
hyperkalaemia 9.9% (placebo 5.5%)
cortisol decreased 5.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence
20 mg
hyperkalaemia 23.6% (placebo 5.5%)
glomerular filtration rate decreased 8.3% (placebo 4.1%)
upper respiratory tract infection 4.2% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence
10 mg + 10 mg
hyperkalaemia 15.1% (placebo 5.5%)
glomerular filtration rate decreased 11% (placebo 4.1%)
hypotension 5.5% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 20 mg
glomerular filtration rate decreased 9.5% (placebo 4.1%)
hyperkalaemia 9.5% (placebo 5.5%)
upper respiratory tract infection 5.4% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
10 mg + 3 mg
hyperkalaemia 6.6% (placebo 5.5%)
glomerular filtration rate decreased 5.3% (placebo 4.1%)
cortisol decreased 2.6% (placebo 0%)
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
3 mg
hyperkalaemia 11.4% (placebo 5.5%)
cortisol decreased 4.3% (placebo 0%)
upper respiratory tract infection 2.9% (placebo 2.7%)
NCT05182840 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Empagliflozin

Time to Cardio-renal Composite Endpoint 6.85% (n=3304) vs 8.96% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
show 1 more result
8.36% (n=3304) vs 9.99% (n=3305) placebo10 mg
NCT03594110 · Phase 3
Time to Cardiovascular Composite Endpoint 2.04% (n=3304) vs 2.39% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Overall Survival 0.1% vs 0.1% placebo10 mg
time to event · count
NCT03594110 · Phase 3
Time to Composite Renal Endpoint 6.09% (n=3304) vs 8.09% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
show 1 more result
7.52% (n=3304) vs 8.95% (n=3305) placebo10 mg
NCT03594110 · Phase 3
Time to CV Death 0.91% (n=3304) vs 1.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to CV Death or ESKD 2.55% (n=3304) vs 3.45% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to Death or ESKD 5.13% (n=3304) vs 6.08% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
Time to ESKD 2.72% (n=3304) vs 3.49% (n=3305) placebo10 mg
event count · % of participants
NCT03594110 · Phase 3
UACR 0.483 vs 0.708 Empagliflozin ratio @ 25.7wk
ratio to baseline · ratio
NCT05254002 · Phase 2 · registry result, not featured evidence
show 2 more results
0.483 vs 0.683 Finerenone ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.818 vs 0.853 Finerenone ratio @ 30wk
NCT05254002 · Phase 2 · registry result, not featured evidence
eGFR 30% Decline 6.3% (n=268) vs 3.8% (n=264) Finerenone @ 4.3wk
event count · % of participants
NCT05254002 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
UACR -0.496 vs -0.027 placebo mg @ 14wk10 mg
absolute change · mg
NCT05182840 · Phase 2 · registry result, not featured evidence
show 5 more results
-0.455 vs -0.027 placebo mg @ 14wk20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
-0.21 vs -0.112 Empagliflozin mg @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.614 vs -0.112 Empagliflozin mg @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.516 vs -0.112 Empagliflozin mg @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-0.254 vs -0.027 placebo mg @ 14wk3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
UACR -39.1% (n=61) vs -2.6% (n=69) placebo @ 14wk10 mg
percent change · % of baseline
NCT05182840 · Phase 2 · registry result, not featured evidence
show 5 more results
-36.6% (n=59) vs -2.6% (n=69) placebo @ 14wk20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence
-19% (n=63) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-45.9% (n=60) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-40.3% (n=62) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · registry result, not featured evidence · combination
-22.4% (n=65) vs -2.6% (n=69) placebo @ 14wk3 mg
NCT05182840 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Empagliflozin's landscape · Enavogliflozin's landscape